TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Modified Melasma Area Severity Index (mMASI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician global evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: A five-point Likert scale for patient's satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline of skeletal muscle pACC/tACC ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in scores of caregiver self-report of psychological distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in scores in caregiver proxy-report of child emotional distress, ages 2-11
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in scores in child self-report and caregiver proxy-report of child Quality of Life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in scores in child self-report and caregiver proxy-report of child Posttraumatic Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in scores in child self-report (ages 6-11) of child depression; Caregiver self-report of caregiver depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in asthma controller regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with clinically significant abnormal laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with clinically significant abnormal vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with suicidal ideation and changes in Columbia Suicidality Rating Scores (CSSRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of patients with repeat ED visits associated with a fall
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: modified Rankin Scale (mRS) at 180 days
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of treatment emergent events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participant tear samples collected
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Caries color related to history of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caries color related to ICDAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caries color related to pulp exposed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caries color related to microbial load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in oral hygiene (plaque index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in oral hygiene (bleeding on probing index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of 18F-PEG3-FPN PET/MR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean of gamma camera views
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consistency between reference strategy and cci-MR strategy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial colonization of DJS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in mitochondrial oxidative capacity in peripheral blood mononuclear cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting subcutaneous interstitial fluid glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial subcutaneous interstitial fluid glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients with good functional outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adherence to treatment-window
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Minimum intracuff pressure at which there is no air leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention to the study at 3 months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Retention to the study at 6 months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum tolerated dose (MTD) of JS014
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase-2 dose (RP2D) of JS014
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Semi-quantitative SUV analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinetic modelling (Patlak, Ki) analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Child Developmental Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Child Participation and Recreational Activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Child Participation and Self-care Activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Adipocyte Necrosis After Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inflammatory Immune Response Vs. Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean error of differences between CART BP and Reference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard deviations of differences between CART BP and Reference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction Measure
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in symptoms (Functional Assessment of Cancer Therapy General - FACT-G)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in symptoms (Patient Health Questionnaire - PHQ-9 Item)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in symptoms (Generalized Anxiety Disorder - GAD7 Item)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in symptoms (Quality of Life and Satisfaction Questionnaire - Q-LES-Q)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Complete recovery without relapse
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: accuracy of Robotic Assisted Surgery and Gyroscopic Based Instrument
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Durability of closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Systematic Coronary Risk Evaluation 2 risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in PGRN levels in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PGRN levels in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance (Cl) of cefepime
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance (Cl) of iohexol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance (Cl) of meropenem
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Left Ventricular Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of prespecified safety events
Endpoint domain: Adverse events/effects
Primary endpoint: LAA occlusion defined as no peri-device flow or peri-device flow ≤5mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of nonserious adverse events leading to permanent discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) for Lithium in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration versus Time Curve From Time Zero to Last Quantifiable Sample (AUC0-last) for Lithium in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (Maximum Concentration) for Lithium in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of marstacimab-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of marstacimab-related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiac structure measurements (LV mass, LVEDV, LVESV, wall thickness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in health status (MLHFQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of TRX103 infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Least Square Mean Change from Baseline in Schiff Sensitivity Score at Day 15
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: LS Mean Change from Baseline in Tactile Threshold at Day 15
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of Technical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of serious adverse events (SAEs) considered related to vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of Elecsys® Troponin T hs Gen 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vital signs (Systolic and diastolic Blood Pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Spirometry (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Abbreviated Composite Autonomic Symptom Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ewing Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intraplaque hemorrhage (IPH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in baseline 30-s chair stand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year rate of any axillary recurrence
Endpoint domain: Mortality/survival
Primary endpoint: 5-year rate of isolated axillary recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Comparison of 5-year rate of axillary recurrence in patients treated with and without axillary dissection
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy of HUNS001-01
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants that complete all 8 weeks
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change BDI-II Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole blood ROS production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length-for-age Z score (LAZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMSE scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: average airway pressure (PAWM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: esophageal pressure (PES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: PaCO2 (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Physical activity (min/week)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage meeting physical activity guidelines
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Back pain VAS responder rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC0-T,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type, incidence, and severity of treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of children with IgG SARS-CoV-2 antibodies in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum Observed Serum Concentration (Cmax) of ABBV-142
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Serum Concentration-time Curve (AUC) of ABBV-142 from Time 0 to the Time of Last Measurable Concentration (AUCt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite number of adverse pregnancy outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of microscopic metastases detected by fluorescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Heart block incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Participant Burden
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Real-world Objective Response Rate (rwORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Glucose Time in Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Major aortic complications (MAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to death or new episode of acute decompensation
Endpoint domain: Mortality/survival
Primary endpoint: Acceptability of TiMBRe
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Demand of TiMBRe
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence to TiMBRe
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Practicality of TiMBRe
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Percent change in inflammatory lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Occurrence of acute kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Agreement of blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Agreement of heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of messages generated by participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of biomarker deficits at ICU admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative hypoesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in functional impairment (WHO-DAS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in functional impairment (IPF)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in psychiatric distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in quality of life (WHOQOL-BREF)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in quality of life (Quality of Life Scale)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in number of days of drugged driving
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cure rate of emodepside against Strongyloides stercoralis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of atrial fibrillation (AF) attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total postoperative pethidine consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Geometric mean concentration (GMC) of anti-gE antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seropositivity rate of anti-gE antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: The incidence and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Cancer therapy-related cardiovascular toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: UWS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of CAD EYE system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in peripheral muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in inspiratory/expiratory muscle strength (MIP/MEP) (cmH2O)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cardiorespiratory fitness: maximal oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitochondrial respiratory chain function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histopathology of duodenal biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Agreement between risk score and actual flares
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Rankin scale (mRS) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: soothing effect on dentin hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-Spike IgG titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain score with movement at 24 hours after delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 90-day death adjusted cumulative incidence of variceal rebleeding
Endpoint domain: Mortality/survival
Primary endpoint: Stability of amount of healthy tooth structure exposed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DNA Fragmentation Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progressive Motility Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early Apoptosis Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normal Morphology Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standardized symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of Posterior Pelvic Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Perceived Difficulty with ASLR Task
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Time to ASLR Fatigue Task Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Failure Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Taste and salivary disturbance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of substance-using days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention of participants in the Opioid Agonist Therapy Program
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Sleep Onset Latency Change from Baseline
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Relative change in peak Standardized Uptake Values (SUVs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical pulp testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radio graphic pulp testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematology blood test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serology blood test - HBV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serology blood test - Hepatitis C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serology blood test - HIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Chemistry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response (OR) defined as best overall response (BOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Form of IgA nephropathy (progressive or stable)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: CGM prescription rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Upper airway pressure-flow/area relationships
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maternal Fever Incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maternal Tachycardia Incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes